NRX Pharmaceuticals earnings date
NRX Pharmaceuticals (B1Q) Q3 2026 Earnings Report
DE:B1Q Q3 2026 EPS Results
- Actual EPS
- -EUR 0.05
- Consensus EPS
- -EUR 0.19
- Beat/Miss
- Beat by +EUR 0.15
- One Year Ago EPS
- -EUR 0.25
DE:B1Q Q3 2026 Revenue Results
- Actual Revenue
- EUR 1.06M
- Expected Revenue
- EUR 1.17M
- Beat/Miss
- Missed by -EUR 114.91K
- YoY Revenue Growth
- +378.93%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/17/2026
- Time
- Before Open
- Conference Call
- Tuesday, November 17, 2026
NRX Pharmaceuticals's next earnings date is estimated for April 1, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was predominantly positive, emphasizing NRx's transition from a development-stage company to a commercial pharmaceutical company, its first FDA approval, first customer order, growing patient revenue, cash balance of approximately $20 million, four operating divisions, and multiple 2027 development and profitability objectives. The company continues to report operating losses, higher expenses, dilution concerns, and regulatory and clinical uncertainties, but the number and significance of stated achievements outweighed the challenges.
NRx aims for a commercially successful 2027, to demonstrate a path to profitability, and believes NRX-100 can be approved in 2027; it expects to submit a rolling NDA for NRX-100 by the end of this year, with regular approval supported by more than 500 patients of randomized clinical trial data and 65,000 patients of real-world evidence, or accelerated approval requiring confirmatory data within 5 years. NRX-200 will enter pharmacokinetic testing in early 2027, with a first-in-human clinical trial targeted for September 2027. More than 400 patients are expected to be enrolled and treated in 2027 in the SPARC-TMS trial and planned military hospital arm, with the trial scheduled to read out in early 2028. NRx expects its preservative-free ketamine market to be approximately $400 million a year and growing at more than 17% a year, believes it can manufacture 4 million or 5 million units a month, and would be very happy if it took 20%, 30% of the market; it also said adding a few similar sterile products could double or triple its currently addressable market in early 2027.
- First FDA Drug ApprovalOn October 29, 2026, FDA approved NRx's abbreviated new drug application for preservative-free ketamine, the company's first drug approval and the first approval of a blow-fill-seal Luer-Lock vial as a drug-device combination.
- Commercial Launch and First Customer OrderNRx has a 17-person veteran sales force in the field, and the company received its first order for preservative-free ketamine during the quarter.
- Improved Cash Position and No Convertible DebtNRx ended the third quarter with approximately $20 million in cash and cash equivalents, reported as approximately $19.8 million by the CFO, versus $7.8 million at December 31, 2025. The company stated that it has shed all convertible debt from its balance sheet. The increase in cash was primarily related to a public offering with gross proceeds of more than $22 million.
- Patient Revenue GrowthNet patient revenue increased to $1.2 million in the third quarter of 2026 from $0.2 million in the third quarter of 2025.
- Reduced Nine-Month Net LossFor the nine months ended September 30, 2026, NRx reported a net loss of $20.1 million versus $29 million in the comparable period of 2025. The company attributed the change primarily to fair-value accounting measurements and nonrecurring charges related to convertible-note conversion and restructuring incurred during the 2025 period.
- Sterile Injectable Market OpportunityNRx estimates the U.S. demand for sterile injectable ketamine at approximately $400 million annually, growing at more than 17% a year. The company stated that adding several similar sterile products could double or triple its currently addressable market in early 2027, while the broader U.S. generic sterile-products market is estimated at $23 billion.
- Blow-Fill-Seal Manufacturing AdvantageNRx stated that 900,000 blow-fill-seal units can be manufactured in the time required to fill, stopper, crimp-cap and package 50,000 glass bottles. The company anticipates COGS of approximately $0.75 per blow-fill-seal unit versus roughly $3.25 per unit for glass packaging.
- Packaging and Hospital Workflow BenefitsThe company stated that its Luer-Lock vial does not generate sharps medical waste, reduces handling steps compared with traditional glass vials, and received high user satisfaction and considerable medical-staff time savings in NRx human-factor studies. NRx also cited approximately 385,000 reported needle-stick and other sharps injuries among U.S. hospital healthcare personnel annually.
- NRX-100 Regulatory ProgressNRx plans to submit a rolling NDA for NRX-100 by the end of 2026 and believes the product can be approved in 2027 through either regular or accelerated approval. The planned regular-approval submission includes more than 500 randomized clinical-trial patients and 65,000 patients of real-world evidence.
- Yale and PCORI CollaborationNRx signed a collaboration agreement with Yale University and, with PCORI's written approval, joined as sponsor of a study comparing IV ketamine with intranasal S-ketamine. The study is intended to provide confirmatory data within five years for the accelerated-approval pathway.
- NRX-101 DARPA-Funded TrialDARPA awarded NRx Defense Systems an $11.2 million initial prime contract to lead the Phase 2/3 SPARC-TMS trial of NRX-101 with rapid robotic transcranial magnetic stimulation. More than 400 patients are expected to be enrolled and treated in 2027, with the trial scheduled to read out in early 2028.
- NRx Defense Systems MilestonesNRx Defense Systems satisfied its initial DARPA milestones, and its first two invoices were approved for payment in the fourth quarter of 2026. The company stated that the division is expected to be funded through nondilutive capital, become profitable, and provide a modest contribution margin to the NRx parent company.
- HOPE Therapeutics Expansion and Technology AdoptionHOPE Therapeutics generated its first clinical revenue in the fourth quarter of 2025 and operated six locations in Florida as of September 30, 2026. It partnered with Zeta Surgical to implement robotic neuronavigated TMS and has treated its first patients with the technology.
- NRX-200 Subcutaneous Ketamine ProgramNRx developed and demonstrated the feasibility of a proprietary neutral-pH ketamine formulation using an FDA-approved cyclodextrin vehicle exclusively licensed to NRx. NRX-200 is expected to enter pharmacokinetic testing in early 2027, with a first-in-human clinical trial targeted for September 2027.
- NRX-101 Clinical Data and Product ReadinessNRX-101 received FDA breakthrough therapy designation and demonstrated reductions in depression, suicidality and akathisia, with superiority to lurasidone in two randomized controlled trials for relieving akathisia and suicidality. The DARPA-funded trial uses NRX-101 at 175 milligrams of D-cycloserine and 7.5 milligrams of lurasidone, with matching placebo and drug supply ready for patient enrollment.
- GeNeuro ALS and Schizophrenia OpportunityGeNeuro is pursuing potential disease-modifying treatments for ALS and schizophrenia. NRx stated that 70% of people with ALS seen at the National Institutes of Health have HERV-K envelope protein in cerebrospinal fluid, and that preclinical testing showed GNK-301 blocked the toxic effect in relevant experimental systems. GeNeuro also has Temelimab, an antibody tested in multiple human trials, which NRx intends to evaluate for schizophrenia.
- Planned GeNeuro Science DayNRx plans to hold a GeNeuro Science Day during the first week of December 2026 to present the science and development opportunity.
- Four-Division Corporate StructureNRx operates four divisions: NeuroRx Pharmaceuticals, including innovative and sterile injectable products; HOPE Therapeutics; NRx Defense Systems; and GeNeuro. Management stated that each division is intended to be financed through mechanisms potentially nondilutive to NRx shareholders and has a near-term opportunity to become profitable in its own right.
- 2027 Profitability ObjectiveManagement stated that its goal for 2027 is to build a commercially successful company that demonstrates profitability while funding innovation from nondilutive sources whenever possible.
DE:B1Q Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Apr 01, 2027 | 2026 (Q4) | -0.21- | -0.04 | ― | ― |
| Nov 17, 2026 | 2026 (Q3) | -0.19-0.05 | -0.25 | 81.48% (+0.20) | |
| Aug 17, 2026 | 2026 (Q2) | -0.10-0.40 | -0.89 | 55.10% (+0.49) | |
| May 18, 2026 | 2026 (Q1) | 0.19-0.04 | -0.31 | 88.24% (+0.27) | |
| Mar 24, 2026 | 2025 (Q4) | 0.010.01 | -0.66 | 101.38% (+0.67) | |
| Nov 17, 2025 | 2025 (Q3) | -0.02-0.25 | -0.14 | -80.00% (-0.11) | |
| Aug 18, 2025 | 2025 (Q2) | -0.14-0.89 | -0.68 | -30.67% (-0.21) | |
| May 15, 2025 | 2025 (Q1) | -0.26-0.31 | -0.67 | 54.05% (+0.36) | |
| Mar 17, 2025 | 2024 (Q4) | -0.33-0.66 | -0.46 | -44.80% (-0.20) | |
| Nov 14, 2024 | 2024 (Q3) | -0.51-0.14 | -0.64 | 78.57% (+0.50) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

